All News

Compared with their peers receiving injectable treatments for their relapsing-remitting multiple sclerosis (RRMS), children who received newer disease-modifying therapies (DMTs) had improved scores on several measures of disease progression.

Individuals with insomnia had 1.41 times the risk of developing hypertension, compared with people without the sleep disorder.

Results of a systematic review underscore implications of increased rates of metabolic syndrome among youth with type 1 diabetes.

Patients with atopic dermatitis (AD) benefit from extensive patient education. A new report suggests group-based sessions are preferred to individual educational sessions or fun activities.

An initiative launched with the intent to deliver equitable cancer care improved the enrollment rates of Black participants in cancer clinical trials by focusing on community outreach and engagement.

Rebecca Spencer, PhD, professor, Department of Psychological and Brain Sciences, University of Massachusetts Amherst, and co-chair of SLEEP 2021, highlights takeaways from this year’s meeting and discussions she’s looking forward to.

People-first language should be a cultural norm, with patients’ best interests always coming first, and we must encourage everyone to become change agents, according to Milena Murray, PharmD, MSc, BCIDP, AAHIVP, Midwestern University College of Pharmacy.

A study out of Israel shows Pfizer’s COVID-19 vaccine is highly effective in patients with cancer; women with alcohol disorders face adverse health consequences sooner; hundreds of thousands of doses of Johnson & Johnson’s COVID-19 vaccine may expire in June.

Michael Thompson, president and CEO of the National Alliance of Healthcare Purchaser Coalitions, discussed findings of his organization’s Pulse of the Purchaser survey that signaled a return to a stabilized business environment.

Camille Hertzka, vice president and head of oncology, US Medical, AstraZeneca, speaks on how the OlympiA findings may warrant greater need of genetic testing for BRCA mutation and the efficacy of olaparib by patient subgroup.

Progressive rehabilitation produced superior results among patients randomized to a 36-session program during or following hospitalization for acute decompensated heart failure vs those randomized to usual care.

With 5 chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, and 299 agents in the pipeline, it’s no surprise that the virtual meeting of the European Hematology Association (EHA) will have a heavy presence of CAR T research being presented in sessions and posters.

FDA and ASPR issue policy recommendations to reform US pharmaceutical supply chains; insurer coverage implications of the newly approved therapy in Alzheimer disease; Apple announces new health data sharing features.

A study examining how US biosimilar uptake has evolved found that biosimilars launched more recently have seen better uptake than biosimilars that have been on the market for a longer period.

The researchers created a model that simulated what would happen when health systems and providers began working together in Medicare accountable care organizations (ACOs) in arrangements that did not extend to outright mergers or acquisitions.

Rajat Bannerji, MD, PhD, Chief, Section of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, speaks on the efficacy and safety findings of the CAPTIVATE study examining the fixed-duration regimen of ibutinib and venetoclax combination therapy in CLL.

Results of a nationwide study show earlier onset of type 1 diabetes (T1D) is associated with worse glycemic outcomes and presence of albuminuria.

Adherence to antiretroviral therapy (ART) can be improved by health care providers reinforcing ART dispensing models and creating ART models that promote situational stability, according to a new study.

Almost half of US migraineurs hesitate to seek out care for their condition, according to research presented at the American Headache Society's 63rd Annual Scientific Meeting.

The FDA approves a new drug for Alzheimer disease; COVID-19–related hospitalization rates are on the rise among adolescents; efforts to address racism, discrimination, and implicit bias in health care; the United States will send 1 million Johnson & Johnson COVID-19 vaccines to Mexico cities along the border and resorts.

Shalini Paruthi, MD, medical codirector, St. Luke’s Hospital Sleep Medicine and Research Center, and cochair of SLEEP 2021, discusses the sessions and discussions she is looking forward to at this year's meeting.

Farrah Kheradmand, MD, elaborates on the effects of marijuana legalization and increased recreational use on research into electronic cigarettes.

Camille Hertzka, vice president and head of Oncology, US Medical, AstraZeneca, discussed updated findings of the PACIFIC trial that indicated a third of patients with unresectable non-small cell lung cancer are stable at 5 years.

The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.

Antoine Italiano, MD, PhD, head of Early Phase Trials and Sarcoma Units at Institut Bergonié, Bordeaux, France, addresses findings of an extended follow-up of larotrectinib in patients with TRK fusion cancer that indicated prolonged progression-free survival in those undergoing the NTRK inhibitor.

The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.

Kirk Shepard, MD, chief medical officer, senior vice president, and head of Global Medical Affairs, Eisai, discusses findings of a study showcasing similar health-related quality of life (HRQOL) scores between lenvatinib/pembrolizumab vs chemotherapy in patients with advanced endometrial carcinoma.